Related references
Note: Only part of the references are listed.Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney et al.
EUROPEAN HEART JOURNAL (2022)
High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients
Rafael Escate et al.
CARDIOVASCULAR RESEARCH (2021)
Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
Ulf Landmesser et al.
CARDIOVASCULAR RESEARCH (2021)
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Zhiyong Qi et al.
CIRCULATION (2021)
Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers
Anders Hovland et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2021)
LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
Aleksandra Gasecka et al.
LIFE-BASEL (2021)
Pleiotropic Effects of PCSK-9 Inhibitors
Marcin Basiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery
Chan Joon Kim et al.
CARDIOLOGY JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome
Hideki Yano et al.
JOURNAL OF CARDIOLOGY (2020)
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
Cristina Barale et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
PCSK9 inhibitors and cardiovascular outcomes
Daniel Steffens et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities
A. Vuorio et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction
Aleksandra Gasecka et al.
PLATELETS (2020)
Inflammaging and platelet hyperreactivity: A new therapeutic target?
Joshua Price et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice
Aida A. Korish
ARCHIVES OF MEDICAL RESEARCH (2020)
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Gregory G. Schwartz et al.
CIRCULATION (2020)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Nicholas A. Marston et al.
CIRCULATION (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease This
Laith N. AL-Eitan et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2020)
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
Constantine E. Kosmas et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
Agnieszka Mickiewicz et al.
CARDIOLOGY JOURNAL (2019)
Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction
Jin Sup Park et al.
CARDIOLOGY JOURNAL (2019)
Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione
Mohamed Mahmoud El-Seweidy et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions
Aleksandra Korniluk et al.
MEDIATORS OF INFLAMMATION (2019)
PCSK9 inhibition and inflammation: A narrative review
Massimiliano Ruscica et al.
ATHEROSCLEROSIS (2019)
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Patricia Marchio et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
PCSK9 and inflammation: a review of experimental and clinical evidence
Amir Abbas Momtazi-Borojeni et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
CD36 and ERK5 link dyslipidemia to apoptotic-like platelet procoagulant function
Moua Yang et al.
CURRENT OPINION IN HEMATOLOGY (2019)
Platelet-derived microparticles promote phagocytosis of oxidized low-density lipoprotein by macrophages, potentially enhancing foam cell formation
Can Feng et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies
Ruurt A. Jukema et al.
BMC MEDICINE (2019)
Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles
Gemma Chiva-Blanch et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Ticagrelor suppresses oxidized low-density lipoprotein-induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE-/- mice via downregulation of PCSK9
Xiaodong Xia et al.
MOLECULAR MEDICINE REPORTS (2019)
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
Francesco Paciullo et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Platelet and Leukocyte Activation
Aida Collado et al.
JOURNAL OF CLINICAL MEDICINE (2019)
PCSK9 inhibition in the management of familial hypercholesterolemia
Masatsune Ogura
JOURNAL OF CARDIOLOGY (2018)
Oxidative burden in familial hypercholesterolemia
Hamid Mollazadeh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Improved endothelial function after short-term therapy with evolocumab
Guglielmo Maulucci et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA
Eric Boilard
JOURNAL OF LIPID RESEARCH (2018)
The Evolving Future of PCSK9 Inhibitors
Robert S. Rosenson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Effect of Change in Total Cholesterol Levels on Cardiovascular Disease Among Young Adults
Su-Min Jeong et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease
Asier Benito-Vicente et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia
Cristina Barale et al.
BIOMED RESEARCH INTERNATIONAL (2018)
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy
Q. Feng et al.
PHARMACOGENOMICS JOURNAL (2017)
Platelet extracellular vesicles as biomarkers for arterial thrombosis
Aleksandra Gasecka et al.
PLATELETS (2017)
Alirocumab for the treatment of hypercholesterolemia
Brian Tomlinson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells
Tobias Becher et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control study
Thuhairah Rahman et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
Hui Wang et al.
SCIENTIFIC REPORTS (2017)
Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
Leo E. Akioyamen et al.
BMJ OPEN (2017)
PCI and clopidogrel: antiplatelet responsiveness and patient characteristics
Aleksandra Grdinic et al.
ACTA CARDIOLOGICA (2017)
EFFECTS OF PCSK9 INHIBITORS ON PLATELET FUNCTION IN ADULTS WITH HYPERCHOLESTEROLEMIA
Cristina Barale et al.
ATHEROSCLEROSIS (2017)
Hypercholesterolemia: The role of PCSK9
Quantil M. Melendez et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2017)
Increased Mean Platelet Volume in Familial Hypercholesterolemia
Atilla Icli et al.
ANGIOLOGY (2016)
PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
Jin M. Cheng et al.
ATHEROSCLEROSIS (2016)
Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
Vera Bittner
CIRCULATION (2016)
Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease
William Herrington et al.
CIRCULATION RESEARCH (2016)
Statins and Their Effect on PCSK9-Impact and Clinical Relevance
Beth A. Taylor et al.
CURRENT ATHEROSCLEROSIS REPORTS (2016)
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2016)
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia
Amit V. Khera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
Marian McDonagh et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2016)
The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe
Sergio Fazio
ATHEROSCLEROSIS SUPPLEMENTS (2015)
Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Ann Marie Navar-Boggan et al.
CIRCULATION (2015)
PCSK9 and its modulation
Chuan-Jue Cui et al.
CLINICA CHIMICA ACTA (2015)
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
A. Sahebkar et al.
DIABETES OBESITY & METABOLISM (2015)
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
John J. P. Kastelein et al.
EUROPEAN HEART JOURNAL (2015)
PCSK9: A key factor modulating atherosclerosis
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis
Rosa Suades et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Evolocumab (AMG 145) for primary hypercholesterolemia
Gisle Langslet et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2015)
Platelets Mediate Oxidized Low-Density Lipoprotein-Induced Monocyte Extravasation and Foam Cell Formation
Sigrun Badrnya et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism
Roberto Carnevale et al.
ATHEROSCLEROSIS (2014)
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy
L. M. Camargo et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
Eli M. Roth et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Platelets and their chemokines in atherosclerosis-clinical applications
Philipp von Hundelshausen et al.
FRONTIERS IN PHYSIOLOGY (2014)
LOX-1 in atherosclerosis: biological functions and pharmacological modifiers
Suowen Xu et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
Evolving Role of Microparticles in the Pathophysiology of Endothelial Dysfunction
Fina Lovren et al.
CLINICAL CHEMISTRY (2013)
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study
Philippa J. Talmud et al.
LANCET (2013)
LOX-1: a multiligand receptor at the crossroads of response to danger signals
Tatsuya Sawamura et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
Zhihan Tang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
Lipid-Related Markers and Cardiovascular Disease Prediction
Emanuele Di Angelantonio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano et al.
LANCET (2012)
Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques
Rosa Suades et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Disturbed-Flow-Mediated Vascular Reactive Oxygen Species Induce Endothelial Dysfunction
Kyung-Sun Heo et al.
CIRCULATION JOURNAL (2011)
The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients
Boguslawa Luzak et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Platelets in atherosclerosis
Dirk Lievens et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia
Jonathan Rios et al.
HUMAN MOLECULAR GENETICS (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Oxidized LDL-Activated Platelets Induce Vascular Inflammation
Karin Daub et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2010)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Platelet hyperreactivity, scavenger receptors and atherothrombosis
M. Valiyaveettil et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Inflammation stimulates the expression of PCSK9
Kenneth R. Feingold et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis
Dorothea Siegel-Axel et al.
CARDIOVASCULAR RESEARCH (2008)
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Eugene A. Podrez et al.
NATURE MEDICINE (2007)
Platelets induce differentiation of human CD34+ progenitor cells into foam cells and endothelial cells
Karin Daub et al.
FASEB JOURNAL (2006)
Scavenger receptors in atherosclerosis: Beyond lipid uptake
Kathryn J. Moore et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion
LQ Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
CD36 is a sensor of diacylglycerides
K Hoebe et al.
NATURE (2005)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia
PL van Haelst et al.
CLINICAL SCIENCE (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Activated platelets induce secretion of interleukin-1β, monocyte chemotactic protein-1, and macrophage inflammatory protein-1α and surface expression of intercellular adhesion molecule-1 on cultured endothelial cells
JK Cha et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2000)
Share Paper
